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We aimed to develop an animal model of long-term blood pressure variability (BPV) and
to investigate its consequences on aortic damage. We hypothesized that day-to-day
BPV produced by discontinuous treatment of spontaneously hypertensive rats (SHR)
by valsartan may increase arterial stiffness. For that purpose, rats were discontinuously
treated, 2 days a week, or continuously treated by valsartan (30mg/kg/d in chow) or
placebo. Telemetered BP was recorded during 2min every 15min, 3 days a week
during 8 weeks to cover the full BP variations in response to the treatment schedule.
Pulse wave velocity (PWV) and aortic structure evaluated by immunohistochemistry were
investigated in a second set of rats treated under the same conditions. Continuous
treatment with valsartan reduced systolic BP (SBP) and reversed the aortic structural
alterations observed in placebo treated SHR (decrease of medial cross-sectional area).
Discontinuous treatment with valsartan decreased SBP to a similar extent but increased
the day-to-day BPV, short term BPV, diastolic blood pressure (DBP), and PWV as
compared with continuous treatment. Despite no modifications in the elastin/collagen
ratio and aortic thickness, an increase in PWV was observed following discontinuous
treatment and was associated with a specific accumulation of fibronectin and its
αv-integrin receptor compared with both groups of rats. Taken together the present
results indicate that a discontinuous treatment with valsartan is able to induce a significant
increase in day-to-day BPV coupled to an aortic phenotype close to that observed in
hypertension. This experimental model should pave the way for future experimental and
clinical studies aimed at assessing how long-term BPV increases aortic stiffness.
Keywords: long-term blood pressure variability, diastolic blood pressure, aortic stiffness, pulse wave velocity,
spontaneously hypertensive rats, telemetry, fibronectin
Abbreviations: BP, blood pressure; BPV, blood pressure variability; CV, coefficient of variation; DBP, diastolic blood pressure;
HR, heart rate; MCSA, media cross-sectional area; PWV, pulse wave velocity; SD, standard deviation; SBP, systolic blood
pressure; SHR, spontaneously hypertensive rat; vWF, von Willebrand factor.
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INTRODUCTION
Enhanced aortic stiffness is a significant and independent
risk factor for all-cause of cardiovascular mortality, primarily
coronary heart disease and stroke in man (Laurent et al.,
2006). Despite the association between arterial stiffness and
hypertension, it remains difficult to separate the causal
effects of blood pressure (BP) elevation and changes in
other associated haemodynamic parameters on arterial wall
remodeling (Papadogiannis and Protogerou, 2011).
It is from this perspective that BP variability (BPV) has
become a focus of attention. Several lines of evidence suggest that
BPV is associated with increased cardiovascular risk independent
of BP. Indeed, there is convincing evidence that BPV within 24 h
is an independent predictor of the incidence of cardiovascular
events in man (Mancia et al., 2007, 2012) and produces end-
organ damage in a few experimental models (Van Vliet et al.,
1999; Miao et al., 2003; Bouissou et al., 2014). Long-term visit-
to-visit BPV increase, which potentially reflects a more diverse
set of influences than short-term 24-h BPV, has also recently
been described to independently predict clinical outcomes
(Papadogiannis and Protogerou, 2011).
Results from clinical studies often conflictdue to the variety of
ways to express BPV in man [the standard deviation of BP or its
coefficient of variation and the average real variability (ARV) of
BP], the period selected for the assessment of BPV (day, night,
24-h, or visit-to-visit periods) and the hemodynamic parameter
evaluated (systolic or diastolic BP; Wei et al., 2014; Taylor et al.,
2015).
Nevertheless, long-term intra-individual BPV has little
correlation with concomitant short-term 24-h BPV and may
result from different determinants. Seasonal changes due
to ambient temperature and daylight hours, low patients’
compliance and adherence to antihypertensive treatments or
behavioral changes related to workdays and weekends are
frequently cited as determinants of long term BPV (Mancia et al.,
2012).
Important limitations of the current data from visit-to-
visit BPV have been mentioned and related to the difficulty
in quantifying precisely the magnitude of BP variations seen
clinically and its repercussions on organ damage. Non-invasive
ambulatory BP monitoring is the only approach suitable for
large, long-term studies with BP readings spaced by less than
an half hour to more precisely quantify the magnitude of the
24-h BP variations (Mancia, 2012). Since, these non-invasive
automatic BP measurements require the patient to stop any
activity at the time of measurement, this approach does not
capture true BP variability in real-life conditions. Owing to
the fact that people cannot practically wear an ambulatory BP
cuff all the time, in real-life practice, it is also impossible to
maintain the same frequency of BPmeasurements over long time
periods.
Finally, information on the factors involved in long-term BP
variations are scattered and incomplete. Little is known about the
factors responsible for the BP differences that have been observed
between visits spaced by months or years in observational studies
and antihypertensive drug trials.
For all these reasons, the use of experimental models which
allow BP monitoring and arterial stiffness measurement in
conscious animals via telemetry and the full characterization of
organ damage by ex-vivo methods seem to be an important step
to identify the effects of day-to-day BPV enhancement on the
cardiovascular system.
To our knowledge, no previous study has assessed vascular
damage associated with isolated long-term BPV in experimental
models. We addressed this issue in the development of an
experimental model of day-to-day chronicle BPV increase
based on administration of a discontinuous treatment of anti-
hypertensive drug in spontaneously hypertensive rats (SHR).
To achieve our goal, SHRs were treated with valsartan,
an angiotensin II type 1 (AT1) receptor antagonist, at an
antihypertensive dose, 2 days a week during 8 weeks (Lacolley
et al., 2002). At the end of the treatment, SBP variations, long-
term BPV, pulse wave velocity (PWV), and arterial structure and
composition were investigated.
MATERIALS AND METHODS
Animals
Fifty-one male SHRs (Janvier, Le Genest St Isle, France) were
received at 5 weeks of age and housed in a temperature
and humidity controlled facility with a 12 h light/dark cycle.
They were randomly assigned to a continuous treatment of
placebo or valsartan (30mg/kg/d; (Lacolley et al., 2002)), dosed
pellets (Dietex France), or discontinuous treatment of valsartan
(30mg/kg/d, during 24 h, twice a week every Monday and
Thursday). Treatment began at 8 weeks old and ended at 16
weeks old. All procedures were conducted in accordance with
and approved by the Animal Ethics Committee of the “Ecole
Nationale Vétérinaire d’Alfort” and conformed to the Guide
for the Care and Use of Laboratory Animals, published by the
National Institutes of Health.
Two distinct sets of rats were used for this study:
- Set 1: SHR implanted with a pressure transducer and used for
characterization of BP and BPV (n = 5) for processing and
analysis of telemetered hemodynamics
- Set 2: Rats devoted to PWVmeasurement and arterial structure
analysis (n = 12).
Blood Pressure Recording and Arterial
Measurements
After 1 week of acclimation, 5 SHRs of each group (set
1) were equipped with a telemetric device as previously
described (Basset et al., 2004). In brief, the rats were
anesthetized with sodium pentobarbital (60mg/kg, ip) and kept
on a heating pad throughout the implantation of the BP
telemeter (model TA11PA-C40; Data Sciences International, The
Netherlands). The catheter of the BP telemeter was inserted
into the abdominal aorta. The telemetric transmitter probe was
positioned subcutaneously on the right flank. To reduce any
infection and pain, the rats received amoxicillin (Clamoxyl;
SmithKlineBeecham Laboratories, Nanterre, France; 20mg/kg
ip) and ketoprofen (Profenid; Aventis, Paris, France; 5mg/kg ip).
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The rats were then housed in individual cages placed on the
telemetric receivers, and allowed to recover over 2 weeks. At
the end of the recovery period, treatments and BP recordings
started according to the schedule displayed in Figure 1. Placebo
treated (PT) and continuously treated (CT) groups received
normal chows (0.25% NaCl, Dietex, Saint Gratien, France) and
valsartan encapsulated chows, respectively, everyday throughout
the treatment’s duration. In discontinuously treated (DT) group,
valsartan was given every Monday and Thursday at 10:00 am
and replaced by normal chow every Tuesday and Friday at 10:00
a.m. The exposure to valsartan was thus 24 h twice a week every
Monday and Thursday. The therapeutic withdrawal of 48 h was
chosen to allow the complete elimination between the 2 days of
administration (elimination half-time of Valsartan of 5–7 h for
the rat). In the three groups of rats, BP was recorded every week
from Monday 10:00 a.m. to Thursday 10:00 a.m., during 2min
every 15min. The 2min recordings were averaged to give a value
of BP every 15min yielding 4 BP values per hour and 288 BP
values for the 3 days recording. For each animal, a mean value
of systolic and diastolic BP was calculated each week as the mean
of the 288 SBP values determined over the 3 days recording.
In a second set of experiments, 12 unequipped SHRs from
each group were used for the measurement of PWV as previously
described (Cosson et al., 2007). PWV was performed at the end
of the experiments, the third day of the eighth week. At the
end of the treatment, under pentobarbital anesthesia (60mg/kg,
ip), one catheter was inserted into the lower abdominal aorta
via the left femoral artery; another catheter was introduced,
through the left common carotid artery, into the descending
aorta. Proximal and distal aortic BP signals were simultaneously
recorded on line (Chart version 5.2; AD Instruments) and stored
on a microcomputer (PowerMac 4400/200; Apple) for further
analysis. At the end of the recording, the rats were euthanized
by an overdose of sodium pentobarbital. After dissection, the
tips of the two catheters were visually marked, and the distance
between them was carefully measured three times; the mean
of which was used. For PWV measurement, the foot-to-foot
method was used to determine the time delay between the
proximal and the distal aorta (Cosson et al., 2007). The aorta
and the heart were then removed for evaluation of end organ
damage.
Investigation of Blood Pressure Variability
The spectral analysis of short-term BPV and inter-beat interval
(IBI) was computed with a fast Fourier transform and quantified
in terms of low frequency (LF) and high frequency (HF) spectral
power of SBP and IBI, calculated between 0.2–0.6 and 1.0–2.5Hz,
respectively (Cerutti et al., 1991).
Short term BPV was also characterized by the mean ARV, a
clinical index calculated by the following formula which evaluates
the variability between consecutive and validated readings of BP
(Mena et al., 2005; Hansen et al., 2010):
FIGURE 1 | Schematic representation of a week schedule of treatment and blood pressure (BP) recording. The total duration of treatment was 8 weeks. Int.
treatment, intermittent (i.e., discontinuous) treatment.
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ARV =
1∑
w
n∑
k= 1
w×
∣∣BPk − BPk−1
∣∣
where, k ranges from 1 to n, w is the time interval between BPk−1
and BPk, and n is the number of BP readings in 24 h.
As ARV was never used, to our knowledge, in experimental
models, we first evaluated this index in sino-aortic denervated
(SAD) rats, a relevant model of increased short term BPV. For
that purpose, we used telemetric BP data already published (Van
Vliet et al., 1999). BP data were averaged by sequences of 2min
every 15min to verify that ARV of SAD rats is increased in
conditions of measurements close to those made within our
experiments.
Daily variability was evaluated through the standard deviation
(SD) of the 96 individual values of BP average of 15min periods
over the course of the 24 h recording. Calculation was performed
on the third day of telemetric recording during the eighth week.
As animals were subjected to a controlled 12 h light/dark cycle,
calculation of the weighted 24 h SD, which is the mean of daytime
and nighttime values weighted by the duration of each time
period, was useless in the present study (Bilo et al., 2007).
To evaluate day-to-day variability i.e., long-term variability,
the 3 days recordings of each week were analyzed separately
using Chronos-Fit R© software (Zuther et al., 2009). For each
day, we measured the mean of the SBP and DBP. The long-
term SBP variability was evaluated weekly as the SD of the three
daily means. This method may be compared to the visit-to-
visit variability used to evaluate long-term variability in clinical
studies (Rothwell et al., 2010; Muntner et al., 2011).
Biological Characterization of the Vascular
Endothelium
Plasma was collected before the rats were euthanized. Vascular
endothelium was evaluated through quantification of von
Willebrand factor (vWF) antigen and sCD146, a marker of
the endothelial junctions (Lagrange et al., 2014). vWF was
measured by ELISA (Asserachrom; Diagnostica Stago, Asnière-
sur-Seine, France). Soluble CD146 was measured in plasma using
a homemade ELISA as already reported (Lagrange et al., 2014).
Briefly, costar high-binding 96-well plates (Corning, Corning,
NY, USA) were coated overnight at 4◦C with 100µl of the anti-
CD146 P1H12 clone at 1µg/ml in carbonate-bicarbonate buffer
(0.05 M, pH 9.6). Plates were blocked overnight with 125µl
of PBS containing 0.5% gelatin. Samples (100µl) were assayed
at 2 dilutions (1:5 and 1:10) in PBS containing 0.05% Tween
and incubated for 2 h at room temperature. After subsequent
revelation with the anti-CD146 2Q401 monoclonal antibody
at 1µg/ml for 1 h and horseradish-conjugated streptavidin at
1:1000 for 15min at room temperature, color was developed
with tetramethylbenzidine/H2O2 substrate. Absorbance was
measured in a microplate reader at 450 nm.
Determination of Arterial Structure and
Composition
Arterial structure was determined and quantified in 4%
formaldehyde-fixed thoracic aorta extracted from the rats. The
tissue was extracted from individual paraffin blocks and then
inserted into a preformed paraffin recipient block (Tissue-Tek
Quick-Ray System, Sakura Finetek France). The finished block
was then cut into thick sections and mounted on Superfrost plus
slides and subjected to independent tests.
Collagen, elastin, and media cross-sectional areas (MCSA)
were quantified by morphological analysis after a Sirius
red, orcein and HES (Hematoxillin, Eosin, Safran) staining,
respectively, as previously described (Isabelle et al., 2015).
For immunohistochemical analyses, the following antibodies
were used: a rabbit anti-integrin alpha5 and a rabbit anti-integrin
alphaV (Chemicon International) and a mouse monoclonal
anti-fibronectin (ab2040, Millipore). Immunohistochemistry was
performed on 4µm sections. Heat-mediated antigen retrieval
was performed in EDTA buffer pH 9 in water bath for
30min. Immunostaining was performed on a Dako autostainer
using a peroxidase-labeled polymer-based detection system
(Envision plus, Dako) and diaminobenzidine as a chromogen.
No specific staining was observed when primary antibody was
omitted from the protocol (negative control). The distribution
and quantification of staining were determined by computer-
directed color analysis performed with the Quant’Image software
(Quancoul, Talence, France; Bézie et al., 1998; Bouissou et al.,
2014).
Cardiovascular Damage
Cardiac alteration was evaluated by the heart weight and by the
measure of the BrainNatriuretic Peptide (BNP), amarker of heart
failure. Plasma was collected before the rats were euthanized to
measure the BNP with an Elisa method (AssayMax Rat BNP-32
ELISA Kit, Assaypro, St Charles, USA).
Statistical Analysis
All data are expressed as means ± SEM. One-way ANOVA
followed by a Fisher PLSD was used to assess the significance of
the results. Differences were considered significant at values of
P < 0.05.
RESULTS
Changes in Blood Pressure in Conscious
Rats
The daily changes in BP in each group of treatment regimen
was analyzed by comparing the daily mean SBP and DBP at
the 8th week treatment (Table 1). Compared to PTgroup, both
treatments with valsartan significantly reduced SBP during the
3 days recording. Whilst the effect on SBP appears reduced in
DT compared to CT rats, no significant difference was observed
between the two groups.
In contrast, the DBP decrease observed after continuous
administration of valsartan was less effective in the DT group,
so that DBP was slightly increased in DT vs. CT treatment by
valsartan rats (Table 1).
The time-course changes in BP in the three groups of
conscious rats are displayed in Figure 2. Compared to placebo-
treated rats, both continuous and discontinuous treatments
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TABLE 1 | Telemetered hemodynamic changes in SHR after 8 weeks of
treatment by valsartan.
72h Means Placebo Continuous Discontinuous
treatment treatment
Heart rate, beats min−1 319±4 316± 3 327±4
Systolic blood pressure, mmHg 160.3±5.6 132.8± 7.0* 141.3±5.5*
Diastolic blood pressure, mmHg 114.3±3.3 93.3± 2.0* 105.6±2.5*†
Mean blood pressure, mmHg 129.6±2.5 106.4± 3.3* 117.5±2.1*†
Pulse pressure, mmHg 46.0±3.4 39.6± 4.4* 35.7±4.7*
*p < 0.05 vs. placebo; †p < 0.05 vs. continuous treatment. The values represent
the average of the data acquired during 3 days of recording. Continuous treatment:
administration of valsartan (30mg/kg/d) during the 8 weeks of the experiments.
Discontinuous treatment: administration of valsartan (30mg/kg/d) twice a week (every
Monday and Thursday) during the 8 weeks of the experiments.
by valsartan significantly reduced SBP to a similar extent.
The reduction of the SBP was significant from the beginning
of the data acquisition, the second week of the experiments
(Figure 2A). In contrast, DBP was significantly less reduced in
DT than in CT SHRs (Figure 2B). As a function of the rats getting
older, HR decreased with time and similarly in the three groups
(results not shown).
In the DT group, the increase of DBP was obvious each week
on the third day (day3) of BP telemetered follow-up, i.e., after
2 days of withdrawal of the valsartan (Figure 2D). In contrast,
SBP was only slightly increased on the third day for the same rats
(Figure 2C). These results were confirmed after analysis of the
within-days differences between the first and the fourth quartiles
of BP. Whilst the difference between the first and the fourth
quartiles of SBP was increased in DT vs. CT rats on the first
day of follow-up (i.e., when valsartan was being given for the
discontinuous group after 2 days of withdrawing), SBP fell and
reached the same values the second and the third days of follow-
up after rechallenge of valsartan, indicating a persistent lowering
of the SBP (Figure 2E). In contrast, even if DBP seems controlled
by valsartan on the second day, its values were strongly increased
in DT vs. CT rats during the third day (Figure 2F). Together,
these data confirm that SBP and DBP patterns were different
according to the treatment schedule.
Blood Pressure Variability in Conscious
Rats
The short-term variability of SBP expressed by the low
frequencies of the SBP power spectrum was significantly
decreased by both continuous and discontinuous treatments in
accordance with the reduction in SBP (Figure 3), suggesting
that valsartan reduced the activity of the sympathetic nervous
system.
Table 2 indicates that short term BPV, expressed by ARV
is increased, as expected, in SAD rats. Short-term systolic
and diastolic BPV, expressed by ARV and the SD, were
reduced by valsartan given continuously (Table 3). Nevertheless,
discontinuous treatment by valsartan was unable to reduce
short-term BPV in the same extent. Indeed both systolic and
diastolic ARV and diastolic SD were increased compared to
FIGURE 2 | Time-course evolution of the blood pressure in conscious
rat. Systolic (A) and diastolic (B) blood pressure during the 8 weeks study.
Each point is the mean ± SEM of five rats. For each week and for each rat,
the mean of 288 BP values was calculated (four values of BP per hour
during 3 days recording). *P < 0.05 vs. placebo; †P < 0.05 vs. continuous
treatment. The inter-day evolution of blood pressure during the 8 weeks
study in response to the discontinuous administration of Valsartan is showing
for the systolic (C) and diastolic (D) mean blood pressure. Each point is the
mean ± SEM of the five rats of the discontinuous group. Day 1: Day of
administration of valsartan. Day 2 and Day 3: days of Valsartan’s withdrawal.
The within-day variation of systolic (E) and diastolic (F) blood pressure is
expressed through the difference between the first and the fourth quartile of
blood pressure for the continuously (CT) and the discontinuously (DT) treated
rats with valsartan.
continuous treatment, and comparable to the placebo level 2 days
following the withdrawal of valsartan at the end of the experiment
(Table 3).
In contrast to short-term and daily BPV, day-to-day BP
instability, expressed as the SD over 3 days recording,
was significantly increased by discontinuous treatment with
valsartan, compared to PT and CT groups (Table 3). This result
wasn’t related to the BP level as the average day-to-day SBP and
DBP coefficient of variation were not different between the PT
and the CT rats, these indexes were markedly higher after the
discontinuous treatment by valsartan (Table 3; Figure 4).
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FIGURE 3 | Short term variability evaluated by spectral analysis. Modifications of the low frequencies of systolic blood pressure (A) and high frequencies of
interbeat interval (B) in response to the different treatments schedules. Each bar is the mean ± SEM of five rats. *P < 0.05 vs. placebo.
TABLE 2 | Telemetered hemodynamic changes and their variability in
sinoaortic denervated rats.
SAD (n = 6) Sham (n = 6) P-value
24 H MEANS
Heart rate, beats min−1 400.0± 7.8 398.2±8.0 NS
Systolic blood pressure, mmHg 133.9± 2.9 129.3±1.7 NS
Diastolic blood pressure, mmHg 96.4± 2.6 91.1±1.0 NS
Pulse pressure, mmHg 33.3± 4.7 34.6±2.8 NS
24 H SYSTOLIC BLOOD PRESSURE VARIABILITY
10-min SD, mmHg 10.0± 0.8 8.2±0.5 NS
ARV, beats min−1 7.2± 0.6 4.7±0.4 <0.005
24 H DIASTOLIC BLOOD PRESSURE VARIABILITY
10-min SD, mmHg 9.3± 1.0 7.9±0.6 NS
ARV, mmHg 6.7± 0.8 4.2±0.4 <0.050
24 H PULSE PRESSURE VARIABILITY
10-min SD, mmHg 1.6± 0.2 1.6±0.2 NS
ARV, mmHg 1.2± 0.2 1.0±0.1 NS
SAD, Sinoaortic denervated rats; Sham, Sham-operated rats; Total SD, Mean standard
deviation of values within 144 individual 10min periods over the course of the 24 h
recording; ARV, Average real variability of 24-h.
Aortic Stiffness in Anaesthetized Rats
As in conscious rats, BP was significantly reduced to a similar
extent in both CT and DT groups after the anesthesia (Table 4).
Compared to PT rats, PWV was significantly reduced by a
continuous treatment by valsartan, but remained unchanged
in DT group compared with PT rats (Table 4). Similar results
were obtained when PWV was normalized by DBP (beta
index).
Cardiovascular Damages
A continuous treatment by valsartan significantly reduced heart
weight, while a discontinuous treatment does not (Table 5).
However, BNP plasmatic levels remained unchanged in the three
groups of rats (0.21 ± 0.02mg/L for Placebo vs. 0.18 ± 0.01 and
0.19± 0.03 for CT and DT groups, respectively).
TABLE 3 | Blood Pressure Variability in SHR in response to the different
treatments schedules.
Placebo Continuous Discontinuous
treatment treatment
DIASTOLIC BLOOD PRESSURE
Mean DBP 113.7± 3.5 93.1± 2.2* 107.4±2.3*†
SHORT TERM DBPV
Total SD 24 h 10.8± 0.8 8.8± 0.1* 11.3±1.1†
ARV 8.6± 0.8 7.2± 0.3* 8.6±0.4†
DAY-TO-DAY DBPV
Total SD 0.55± 0.27 0.84± 0.17 2.29±0.42*†
CV 0.47± 0.22 0.91± 0.20 2.14±0.40*†
SYSTOLIC BLOOD PRESSURE
Mean SBP 160.3± 1.0 132.8± 1.1* 141.3±2.6*
SHORT TERM SBPV
Total SD 24 h 12.2± 0.6 9.3± 0.2* 9.7±0.5*
ARV 10.1± 0.9 7.5± 0.3* 9.1±0.4†
DAY-TO-DAY SBPV
Total SD 1.03± 0.36 1.10± 0.25 2.66±0.40*†
CV 0.64± 0.20 0.85± 0.18 1.87±0.25*†
Values are mean ± SEM. *p < 0.05 vs. placebo and †p < 0.05 vs. Continuous treatment.
Continuous treatment: administration of valsartan (30mg/kg/d) during the 8 weeks of
the experiments. Discontinuous treatment: administration of valsartan (30mg/kg/d) twice
a week (every Monday and Thursday) during the 8 weeks of the experiments. DBPV,
Diastolic blood pressure variability; SBPV, Systolic Blood Pressure Variability.
Plasma von Willebrant factor (vWF) was increased in
PT compared with both treated groups (Table 6), indicating
that valsartan preserved endothelium integrity. In contrast,
no difference was found for sCD146 antigen, indicating that
endothelial junctions were not influenced by the treatments.
Immunohistochemical and biochemical characteristics of
aortic structure appear inTable 6. Only the continuous treatment
by valsartan significantly reduced medial wall cross-sectional
area. Vascular collagen and elastin contents and density (Table 6;
Figure 5) as well as size and number of nuclei of smooth muscle
cells (data not shown) remained unchanged in the three groups.
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FIGURE 4 | The Day-to-day variability of diastolic blood pressure (A)
and systolic blood pressure (B) estimated via their coefficient of
variation at the end of the experiments (the 8 week). Each bar is the
mean ± SEM of five rats. *P < 0.05 vs. placebo; †P < 0.05 vs. continuous
treatment.
TABLE 4 | Pulse wave velocity in response to 8 weeks of treatment by
valsartan in Spontaneously Hypertensive rats.
Placebo Continuous Discontinuous
treatment treatment
(n = 7) (n = 7) (n = 5)
Systolic blood pressure, mmHg 208±4 183± 5* 190±10*
Diastolic blood pressure, mmHg 167±3 148± 3* 150±6*
Mean blood pressure, mmHg 187±3 166± 3* 169±7*
Pulse pressure, mmHg 41±2 35± 2 40±4
Heart rate, bpm 336±11 344± 11 347±5
Pulse wave velocity, cm/s 826±46 691± 18* 751±22†
Beta Index (103) 8.8±0.9 6.9± 0.4* 8.0±0.4†
*P < 0.05 vs. placebo and †P < 0.05 vs. continuous treatment.
We observed that fibronectin content was significantly reduced
by continuous treatment as compared to the PT group. In
contrast, fibronectin accumulation was increased in DT group
compared with the two other groups (PT or CT rats; Table 6).
This accumulation of fibronectin was coupled to a specific
increase of its αv-integrin.
DISCUSSION
Using a pharmacological approach to develop an animal model
of long-term BPV, we have shown that discontinuous treatment
TABLE 5 | Effects of valsartan treatments on the weights of various
organs.
Placebo Continuous Discontinuous
treatment treatment
n = 8 n = 8 n = 8
BW, g 370±9 374± 6 385± 7
Heart, g 1.52±0.03 1.37± 0.03* 1.49± 0.02†
Heart:BW, mg/g 0.42±0.01 0.37± 0.01* 0.39± 0.01
Left ventricular, g 1.10±0.03 1.02± 0.02* 1.07± 0.01
Kidney, g 2.66±0.04 2.64± 0.04 2.71± 0.03
Kidney:BW, mg/g 7.3±0.2 7.1± 0.1 7.1± 0.02
Body Weight, BW; The organ: BW ratios (mg/g) were based on the BW measured before
organ extraction. Values are mean± SEM; *p< 0.05 vs. Control; †p< 0.05 vs. continuous
treatment.
TABLE 6 | Aortic structure and composition.
Placebo Continuous Discontinuous
treatment treatment
MCSA, 103 µm2 163.9±0.9 152.6± 1.9* 161.7±1.1†
Elastin, % 31±1.2 30± 0.9 33±0.8
Collagen, % 14±0.9 12± 2.4 15±1.0
Fibronectin, % 14.3±3.1 9.3± 3.3 27.1±5.5†
Integrin α5, % 4.6±2.3 2.8± 0.7 4.4±1.2
Integrin α v, % 2.5±0.8 2.2± 0.8 6.5±2.4*†
VW factor, ng/mL 329.3±14.6 287.3± 8.3* 268.8±13.0*
sCD146, OD450 nm 0.49±0.09 0.43± 0.05 0.34±0.02
Mean ± SEM of 12 rats. MCSA, media cross-sectional area; *P < 0.05 vs. placebo;
†P < 0.05 vs. continuous treatment.
with valsartan, twice a week, is associated with vascular damage in
SHR. This induced change in day-to-day BPV was also associated
with an increase in DBP and PWV, vascular hypertrophy, and
fibronectin accumulation compared to continuous treatment
with valsartan at the same dosage. These changes occurred
despite similar SBP levels between the two groups.
Cross-sectional studies have shown a strong association of
aortic stiffness with age and with cardiovascular risk factors
such as hypertension, obesity, impaired glucose tolerance,
and dyslipidemia (Mitchell et al., 2007). Other hemodynamic
parameters like BPV are also able to reduce arterial elasticity
(Parati et al., 1987; Laurent et al., 2006). The concept that
the degree of variability of BP during a 24 h period bears a
relation to organ damage that is independent of the BP level
comes from animal research (Van Vliet et al., 1999; Su, 2006;
Bouissou et al., 2014). Even if preclinical studies remain an
essential way to explore and understand the relationship between
arterial stiffness and BPV, the inherent cardiovascular risk of
long term BPV has, to our knowledge, never been evaluated
through pharmacological models. To meet this aim, we used
an AT1 blocker (valsartan) with short half-time (6–9 h) twice a
week, every Monday and Thursday, hypothesizing that arterial
pressure would not be controlled on the days for which no
treatment was given, thus inducing day-to-day BPV. Lowering
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FIGURE 5 | Effect of discontinuous treatment by valsartan on abdominal aorta morphological changes examined by adhesion proteins staining (x40).
of BP following drug withdrawal after inhibition of the renin-
angiotensin system in SHR has been performed previously (Paull
and Widdop, 2001; Woolard et al., 2003). These studies reported
a persistant reduction in BP following drug withdrawal coupled
with persistant cardiac hypertrophy a fewweeks later. BPVwasn’t
evaluated, but the absence of hypertensive rebound following
drug withdrawal in these previous studies suggests that day-to-
day variability was marginal. More recently, Susic et al. reported
that in another hypertensive rat model of partial adherence to
antihypertensive therapy, arterial pressure decreased and reached
control values (Susic et al., 2008), but once again, day-to-day
variability wasn’t explored. Thus, to our knowledge, our present
experimental work is the first to report a strong day-to-day
variability in hypertensive rats following discontinuous AT1
blocker treatments.
Telemetric BP recordings were obtained on three continuous
days each week to cover the full BP fluctuations in response
to the peak and trough concentrations of valsartan according
to the treatment schedule. Interestingly, we found a clear
dissociation between diastolic and systolic BP levels in response
to discontinuous drug administration compared with continuous
treatment. The time course evolution of systolic and diastolic
BP levels showed that isolated DBP increased within 2
weeks following the commencement of the discontinuous
drug regimen. In man, epidemiological observations have long
reported that DBP is the strongest predictor of cardiovascular
outcomes below 50 years of age, and with advancing years, a
gradual shift from DBP to SBP and then to pulse pressure (PP)
are the better predictors of coronary heart disease (Franklin et al.,
2001; Li et al., 2014). DBP reflects the resistance the heart must
overcome to eject blood. Increases in DBP therefore, reflects an
increase in peripheral arterial resistance, which in turn might
move reflection sites of the forward BP wave to more proximal
locations, such that the reflected waves return earlier, thereby
augmenting central SBP (Liu et al., 2013). In our present work,
the cardiac mass (body-weight ratio) and plasmatic BNP were
not different between both treated groups of rats indicating that
the increase in DBP in the DT rats is not associated with cardiac
alteration. Also these results strongly suggest that the increased
BPV rather than increased DBP drove the PWV increase in DT
compared with CT rats.
To document arterial stiffness modifications in response to
long-term BPV, we chose to use young rats; an age during which
the rise of BP and remodeling of the arterial wall is predominant.
Indeed, it is well-established that the rise in BP and remodeling of
the arterial wall of conduit arteries occur mostly between the 4th
and 20th weeks in SHR. Therefore, the period of the present study
(8th to 16th weeks of age) was suitable to documentmodifications
in the structural and mechanical characteristics of the aorta
in response to discontinuous antihypertensive treatment. There
is a general consensus that PP provides indirect measure of
arterial stiffness in isolated systolic hypertension (Benetos et al.,
1997; Franklin et al., 1997). Indeed, PP is a strong predictor
of arterial stiffness in hypertensive patients and in the general
population, especially in the elderly. In our study, discontinuous
administration of valsartan caused a significant decrease in
telemetered PP despite the PWV increase compared with rats
treated continuously with valsartan. We have already reported
that in another experimental model of aortic stiffness, SHR
treated with L-Name, PP is obviously not coupled with PWV
and BP (Isabelle et al., 2015). In this model, the absence of a
relation between PWV and PP was related to heart failure as
Frontiers in Physiology | www.frontiersin.org 8 December 2015 | Volume 6 | Article 368
Bouissou-Schurtz et al. Blood Pressure Variability and Stiffness
reported in humans (Regnault et al., 2014). In our present day-
to-day variabilitymodel, cardiac parameters were preserved (data
not shown). Also, our model further demonstrates that a change
in SBP, but not DBP, is the major determinant of PP increase in
different aortic stiffening models (Guo et al., 2014).
After discontinuous treatment with valsartan, we found
an increase in PWV associated with an enhancement of the
medial cross-sectional area of the aorta and accumulation of
fibronectin and its αv-integrins compared with CT rats. Whilst
discontinuous treatment produced the same reduction in very
short term BPV assessed by spectral analysis compared to
continuous treatment, when short term variability was evaluated
by ARV, DT was increased compared to continuous treatment.
This augmentation of ARV occurred on the third day post
treatment and not during the second day, when the blood
pressure was the lowest. Thus, this increase in ARV seems
closely related to the rise of blood pressure. Nevertheless, it may
participate in the vascular alterations as already reported (Miao
et al., 2003; Xie et al., 2003; Bouissou et al., 2014).
Thus, in the absence of a significant difference in SBP,
day-to-day variability appears of the main mechanism to
increase PWV after discontinuous treatment with valsartan. In
addition, the specific accumulation of fibronectin found after
discontinuous treatment compared with placebo treated rats,
despite a significantly lower SBP also support the greater impact
of day-to-day variability as opposed to BP in our model.
Apart from BP, the vascular remodeling process, especially
the extracellular matrix composition, is considered as one of
the major contributors to arterial stiffness. In the present study,
collagen-to-elastin ratio, an index directly associated with the
stiffness of the vascular wall, was unchanged within the different
groups. Therefore, as in other experimental models of increased
stiffness, accumulation of aortic fibronectin and its αv-integrin
receptor appears to be a contributor to PWV inDT rats compared
to CT ones (Bézie et al., 1998; Kakou et al., 2009; Bouissou
et al., 2014). The absence of modification in both CD146 and the
vWF, two biomarkers of endothelial dysfunction (Lagrange et al.,
2014) indicates that the accumulation of the fibronectin observed
in the present experiments results from its in situ synthesis
by the extracellular matrix rather than an accumulation of the
circulating form. In vivo, fibronectin matrix polymerization is
a continuous process, with as much as 50% of the fibronectin
matrix undergoing turnover every 24 h. By contrast, elastin and
collagen are characterized by a very slow turnover (from weeks
to years), fibronectin appears as the main protein playing a
key role in the structural adaptation of the arterial wall in
response to chronic hemodynamic stresses like BP or shear stress
(Sehgel et al., 2015). Indeed, fibronectin is enhanced in a few
animal models of increased arterial stiffness, whether BP level
is increased or not (Lacolley et al., 2002; Bouissou et al., 2014).
Nevertheless, the mechanism for PWV increase in the PT rats
seems quite different, as the accumulation of fibronectin and its
αv-integrin wasn’t present in this group.
Several limitations of our study deserve consideration. First,
hemodynamic parameters and PWV and arterial structure were
investigated in two different sets of animals, excluding therefore
the possibility to correlate day-to-day variability and aortic
damage. Nevertheless, as animals received treatments in the
same conditions, one could speculate that arterial structure and
stiffness was comparable between the two sets of animals. Second,
the groups of rats were relatively small. However, within the
scope of chronic telemetery studies, these numbers were standard
and our results were statistically significant and sufficient to
highlight the role of BP variability on aortic stiffness.
CONCLUSION
Discontinuous treatment by valsartan is able to induce chronic
day-to-day BPV increase in SHR. In this model, we demonstrate
that aortic stiffness, related to fibronectin accumulation, is jointly
associated with BPV. Our results support the notion that BPV is
a precursor to vascular stiffening. Also, this experimental model
should pave the way for future experimental studies aimed at
assessing how long-term variability might lead to an increase
in aortic stiffness. Transposed to humans, the present results
might have important clinical implications in the follow-up of
hypertensive patients.
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